Magnetar Financial LLC Purchases New Shares in Amgen Inc. (NASDAQ:AMGN)

Magnetar Financial LLC bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 20,213 shares of the medical research company's stock, valued at approximately $5,268,000.

A number of other large investors also recently made changes to their positions in the stock. Centricity Wealth Management LLC acquired a new position in Amgen during the fourth quarter valued at approximately $25,000. Legacy Investment Solutions LLC acquired a new position in shares of Amgen in the 3rd quarter valued at $29,000. Synergy Investment Management LLC bought a new stake in shares of Amgen in the 4th quarter valued at $34,000. Atala Financial Inc acquired a new stake in Amgen during the 4th quarter worth $34,000. Finally, Heck Capital Advisors LLC acquired a new stake in Amgen during the 4th quarter worth $36,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Stock Down 0.5 %

AMGN traded down $1.66 during trading on Monday, reaching $314.38. 2,439,369 shares of the stock were exchanged, compared to its average volume of 2,552,998. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The stock's 50 day moving average price is $298.13 and its two-hundred day moving average price is $298.50. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The stock has a market cap of $168.89 billion, a P/E ratio of 41.64, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Remove Ads

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be paid a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.03%. Amgen's dividend payout ratio is 126.09%.

Wall Street Analyst Weigh In

AMGN has been the subject of several recent analyst reports. Citigroup restated a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Piper Sandler Companies restated an "overweight" rating and set a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. StockNews.com cut shares of Amgen from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Finally, Redburn Partners cut their price objective on shares of Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Amgen currently has a consensus rating of "Hold" and an average price target of $314.04.

Insider Transactions at Amgen

In other Amgen news, EVP Jonathan P. Graham sold 25,045 shares of the firm's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares of the company's stock, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is owned by company insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.